Targets › ALPP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.
Alkaline phosphatase that can hydrolyze various phosphate compounds. (UniProt, P05187)
Open in Phaseline: the race on ALPP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai EpimAb Biotherapeutics | EMB-15 Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager | ALPP, ALPG, CD3 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | May 2029 |
Locally Advanced or Metastatic Solid Tumors (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.